Summary
HSBC has initiated coverage on recently listed Manipal Health with a 'Buy' rating and a target price of Rs 1,000, implying a 26% upside. The brokerage anticipates strong growth for the healthcare stock due to improved hospital utilization, the Sahyadri turnaround, a higher-margin specialty mix, and deleveraging, projecting a near-tripling of adjusted PAT by FY29.